|

This Week in Psychedelic Stocks [UPDATES ON MINDMED (MMED/MMEDF) CMPS, NUMI & ATAI, CYBIN]

In today’s episode of “This Week in Psychedelic Stocks”, we’ll see some news on MindMed (MMED / MMEDF/MMQ), Compass Pathways (CMPS), Atai Life Sciences, Numinus Wellness (NUMI), Cybin.

We will cover the latest developments in the field writ large.
This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.

Timestamps:
0:00 – Intro
0:32 – Norway Decriminalization Bill
1:59 – Psychedelic Market Stats
3:21 – Magic Mushrooms to Treat Obesity
5:40 – Ketamine to Treat Suicidal Thoughts?
7:09 -The Acid King?
8:58 – MindMed (MMED/MMEDF/MMQ) Updates
10:04 – Compass Pathways (CMPS) Updates
11:44 – Atai Life Sciences Updates
14:02 – Numinus (NUMI) Updates
15:13 – CYBIN Updates

So this is it for This Week in Psychedelic Stocks fellow psychedelic investors!

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor

Facebook: @thepsychedelicinvestor
Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed​​ ​#MindmedStock​​ #PsychedelicStocks

Similar Posts

  • MindMed To Deliver Psychedelics Directly To The Brain? (MMED / MNMD)

    MindMed (MMED :NEO), (MNMD:NASDAQ), (MMQ: FRA) is testing the delivery of psychedelics compounds directly to the brain!?

    What is the best way to take a psychedelic medicine? Is it in a format of a pill, a film strip which dissolves under the tongue, or maybe an injection? These are the standard delivery methods we’re all familiar with.
    But what if we could deliver a psychedelic medicine directly to the brain, and thus negate any potentially negative side effects of the drug interacting with the body?
    Answering this question is the purpose of a new MindMed partnership.

    In this episode, we’ll explore MindMed’s new partnership with Nextage Therapeutics, their Brain Targeting Liposome System (BTLS), and it’s applications.

    Enjoy the episode!

    Link:
    https://mindmed.co/news/press-release/mindmed-announces-launch-of-collaboration-with-nextage-therapeutics-brain-targeting-liposome-system/

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @thepsychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Website: https://thepsychedelicinvestor.com/
    Music: www.bensound.com
    Video editing: @themyaholy
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #MNMD #MindmedNews

  • Important Correction for MindMed Trials (Plus Changes In MMED/MMEDF’S Timelines)

    What’s up Psychedelic Investors? In today’s episode entitled :Important Correction for MindMed Trials (Plus Changes In MMED/MMEDF’S Timelines), we discuss a correction I have to make to my MindMed (MMED / MMEDF) coverage regarding their clinical trials treating addiction with 18MC, and ADHD with LSD microdoses. The start dates for these phase 2a trials have been postponed until the third quarter of 2021, and have not yet started.

    MindMed is the leader in psychedelic medicines, and is my top Psychedelic Stock. Is MindMed a buy? Is MindMed a good Investment? Watch our channel to find out!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media!
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed #MMED #MMEDF

  • MORE Companies to UPLIST On NASDAQ? Compass Pathways Trial Results & More (CMPS, FTRP, MYCO, CYBN) 🚀

    Compass Pathways (CMPS:NASDAQ) published amazing COMP360 Psilocybin Study results that will serve as support for companies working with psilocybin and psilocybin derivatives. However, this isn’t the only news worth mentioning.
    Field Trip Health (FTRP: CSE) and (FTRPF: OTC) recently uplisted on the TSX ( Toronto Stock Exchange) and has filed an application to uplist on the Nasdaq.
    While this is great news for Field Trip, it is not the only company who has filed to uplist. Silo Pharma, (SILO: OTC), has also put in an application to list on NASDAQ.
    MagicMed will also join the ranks, however it will be through an acquisition.

    Moreover, Cybin (CYBN: NEO,) and (CLXPF: OTC), is working on a transportable, wearable, helmet that completes a brain scan, through a partnership with a company called Kernel.
    There is also news on Mydecine ( MYCO: NEO) and ( MYCOF: OTC) and MindCure (CSE: MCUR) (OTCQB: MCURF), so stay tuned till the end!

    Enjoy the episode!

    Timestamps:

    0:00 – Intro
    0:51 – Compass Pathways COMP360 Study Results
    3:37 – Cybin Ketamine Study
    7:14- Field Trip Uplists on the TSX And Applies To List On The NASDAQ
    11:10 – Silo Pharma Applies To Uplist on The NASDAQ
    12:11 – MagicMed to List On NASDAQ Through Acquisition
    15:16- Mydecine Expands Cultivation Capabilities for Psilocybin
    17:32- MINDCURE Completes First Stage of Manufacturing Synthetic Ibogaine

    Links:
    Compass Pathways Study Results On The Safety And Cognitive Effects Of Taking a Dose Of Psilocybin COMP360:
    https://www.globenewswire.com/news-release/2021/06/03/2241445/0/en/COMPASS-Pathways-and-Kings-College-London-publish-cognition-results-from-COMP360-psilocybin-study-in-healthy-volunteers.html

    Cybin Announces Sponsorship of a Kernel Flow Feasibility Study to Measure Ketamine’s Psychedelic Effects on Cerebral Cortex Hemodynamics
    https://psilocybinalpha.com/news/cybin-announces-sponsorship-of-a-kernel-flow-feasibility-study-to-measure-ketamines-psychedelic-effects-on-cerebral-cortex-hemodynamics

    Field Trip Health Uplists on the TSX:
    https://www.globenewswire.com/news-release/2021/06/03/2241200/0/en/Field-Trip-Health-Ltd-to-Commence-Trading-on-the-Toronto-Stock-Exchange-on-June-7-2021.html

    FTRP Applies To Uplist On NASDAQ:
    https://stockhouse.com/news/the-market-herald-news/2021/06/08/field-trip-health-tsx-ftrp-applies-to-list-on-nasdaq-stock-market

    MagicMed Will Be Acquired by Nasdaq-listed Enveric Biosciences
    https://psilocybinalpha.com/news/magicmed-to-be-acquired-by-nasdaq-listed-company

    Health Canada Has Approved an Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms MYCO: NEO), (MYCOF: OTC) :
    https://finance.yahoo.com/news/health-canada-approves-expansion-mydecine-113000924.html

    MINDCURE, (CSE: MCUR) (OTCQB: MCURF), Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research:
    https://www.prnewswire.com/news-releases/mindcure-successfully-completes-first-stage-of-manufacturing-synthetic-ibogaine-for-use-in-psychedelic-clinical-research-301304810.html

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    editing:@themyaholy
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #CompassPathways #Mydecine #FieldTrip